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Introduction
Up to 25% of older men experience hypogonadism, and 
the prevalence is higher in men with comorbid disease 
(1-5). Hypogonadal men have low serum testosterone 
levels and symptoms of androgen deficiency, including 
a decrease in energy and libido, muscle mass and bone 
density, as well as impairment in cognition and sexual 
function, and depressive symptoms (6). During the past 
decade, there has been increasing awareness of the health 
benefits conferred by testosterone replacement therapy 
(TRT). TRT for hypogonadism increases muscle mass and 
bone mineral density, decreases fat mass, and improves 
mood, libido, and sexual performance (7). However, TRT 
may not be appropriate for all men. The most important 
and controversial implications are with regard to the use of 
testosterone therapy in men with symptomatic testosterone 
deficiency and a history of prostate cancer (Pca). There 
is an historical fear that administration of exogenous 
testosterone may increase risk of developing Pca or an 
aggressive form of the disease. Pca was explained by what 
was called the androgen hypothesis: (I) androgens play a 
key role in the etiology of Pca, (II) high testosterone is 
a risk factor for Pca, (III) low levels of testosterone are 
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protective, and (V) administering testosterone to men with 
existing Pca universally causes rapid growth—something 
every trainee at that time learned was like “pouring gasoline 
on a fire”, or “feeding a hungry tumor”. Although the 
dramatic effects of androgen deprivation therapy in Pca are 
indisputable, current evidence fails to support the concept 
that increasingly high serum testosterone leads to ever-
greater growth of benign or malignant prostate tissue (8). 
Testosterone levels as a risk determinant for Pca
It is a common belief that that higher testosterone levels 
are associated with increased probability of developing 
Pca whereas lower levels of this sexual hormone should be 
associated with a lower risk of developing Pca. A growing 
body of evidence suggests that this is a false myth since 
lower testosterone levels have been associated with a greater 
risk of developing PCa. Additionally lower testosterone 
levels are a negative pathologic predictor of poor outcomes 
in men suffering from Pca. A recent study on men with 
Pca, García-Cruz and co-workers found that testosterone 
level was inversely related the percentage of tumor in the 
biopsy and that lower testosterone levels were related to 
a higher risk of Pca progression (9). In patients treated by 
radical prostatectomy (RP) and low testosterone levels a 
significantly higher incidence of extra-prostatic invasion and 
biochemical recurrence were observed (10). 
A logical question would be whether it is the low 
testosterone that increases the risk of Pca or if it is the Pca 
that increases the risk of having low testosterone. In this 
regard literature seems to support the latter. Significant 
increases in serum testosterone levels and gonadotropins 
have been reported after RP even in the absence of 
androgen deprivation (ADT). Authors found that one year 
after RP, a significant increase in luteinizing hormone (LH) 
and follicle stimulating hormone (FSH) levels was observed 
with a significant increase in the serum testosterone levels. 
Interestingly, men with higher Gleason score (7 to 10) had 
lower serum testosterone levels at baseline with respect to 
men with Gleason score 2 to 6. These data seem to suggest 
that may be a significant impact of high grade Pca on the 
hypothalamic-pituitary axis. Other authors also found that 
Pca exerts an inhibitory effect on testosterone synthesis, 
with a significant increase in testosterone, LH, and FSH 
one yr. ehen tumor is removed by RP (11). Finally, a 
cross-sectional study of 55 men with localized Pca (12) 
showed an increase in the serum levels of LH, FSH and 
dihydrotestosterone (DHT) of 53%, 21% and 13%, 
respectively with no significant changes in any other serum 
hormone investigated. 
TRT in men treated by RP
A study population of 3,886 men with Pca and 6,438 age-
matched controls, found no relationship between Pca risk 
and serum concentrations of testosterone, DHT, or free 
testosterone (13). 
Muller et al. reported on 3,255 men in the placebo arm 
of the reduction by Dutasteride of Pca Events (REDUCE) 
trial who underwent planned prostate biopsies at 2 and 
4 years. and found that baseline serum testosterone and 
DHT levels were unrelated to Pca detection or grade (14). 
No prospective, controlled studies have yet been 
performed with adequate population sizes and duration to 
definitively assess Pca risk with testosterone therapy, but 
evidence to date fails to suggest increased risk. A meta-
analysis of 19 placebo-controlled testosterone therapy cases 
found no significant increase in Pca or development of 
prostate specific antigen (PSA) >4.0 ng/mL in men treated 
with testosterone therapy versus placebo (15). Shabsigh 
et  al .  conducted a systematic review of 11 placebo-
controlled studies and found that men who received 
testosterone therapy had neither increased Pca risk nor 
greater Gleason grade among those who developed Pca (16). 
Several investigators have reported the use of testosterone 
therapy in men after curative treatment for Pca.
Kaufman reported no biochemical or clinical evidence of 
cancer recurrence in seven men who received testosterone 
therapy after prostatectomy, with the longest follow-up 
12 years (17). 
Agarwal et al. reported , no cancer recurrences in ten 
hypogonadal patients with organ confined Pca treated with 
prostatectomy and testosterone therapy (18). Khera et al. found 
that TRT is effective in improving testosterone levels, 
without increasing PSA values, in 57 hypogonadal men who 
have undergone prostatectomy (19). 
Pastuszak et al. performed a review of 103 hypogonadal 
men with Pca treated with testosterone after prostatectomy 
(treatment group) and 49 non hypogonadal men with cancer 
treated with prostatectomy (reference group). There were 
77 men with low/intermediate (non-high) risk cancer and 
26 with high risk cancer included in the analysis. All men 
were treated with transdermal testosterone, and evaluated 
for more than 36 months. Median follow up was 27.5 months, 
at which time a significant increase in testosterone was 
observed in the treatment group. A significant increase in 
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prostate specific antigen was observed in the high risk and 
non-high risk treatment groups with no increase in the 
reference group. Overall 4 and 8 cases of cancer recurrence 
were observed in treatment and reference groups, 
respectively. Although this preliminary data may suggest 
that testosterone therapy may not harm or eventually 
protect against Pca development or recurrence (20), the 
limited number of studied patients and the absence of a 
randomization design do not allow us to generalize these 
conclusions to all patients.
These studies confirm the new concept that testosterone 
therapy may actually protect against Pca development 
or recurrence. Also, emerging data demonstrating that 
androgens promote less aggressive phenotypes and inhibit 
dedifferentiation in some Pca cell lines (21,22). 
Indeed, in a recent publication, San Francisco et al. 
reported that low levels of free testosterone represented 
a significant risk factor for Pca disease reclassification 
(progression) in men undergoing active surveillance (23).
However, it should be recognized that the number of 
reported cases is still small and heterogeneous. There 
is clearly the need to design and conduct randomized 
trials for assessing the impact of TRT on Pca since the 
current recommendations, which suggests to limit TRT to 
symptomatic hypogonadal men successfully treated for Pca 
after a prudent interval, derived from retrospective analyses. 
The timing of T therapy initiation remains undefined. For 
men who underwent RP the “prudent interval” is achieved 
once the PSA is no longer detectable. The situation is 
less simple for men who received radiotherapy since 
undetectable levels might not ever be achieved (7). 
TRT in men treated by curative radiation 
therapy (RT)
Treating hypogonadal men by TRT after RT can pose 
specific and potentially serious problems. A well-known 
phenomenon happening in subjects treated by RT is 
that PSA levels, after this treatment, do not become 
undetectable and a transient increase in the PSA values 
after nadir achievement can cause confusion regarding 
recurrence versus other benign causes. Additionally, short- 
and long-term ADT by LH-RH analogues is considered a 
standard of care in association with RT in intermediate and 
high-risk Pca improving Pca specific mortality and overall 
survival (24,25). The Baylor group retrospectively reviewed 
their data on hypogonadal men (13 patients) receiving TRT 
after treatment with either brachytherapy or external beam 
radiotherapy (EBRT) (20). Four patients fall into a very low 
or low risk for recurrence, seven in the intermediate risk, 
and two in high risk, respectively. Four patients received 
ADT with RT, and three of them also received TRT, which 
was held during treatment. No significant changes in PSA 
were noted during 67.3 months (median 2.5 yrs) of follow-
up. Although the small sample size and the short follow-
up, the authors suggested the use of TRT in hypogonadal 
men treated with curative RT. Sarosdy analyzed 31 patients 
treated with brachytherapy and followed for a mean 
of 60 months (26). Three patients received combined 
EBRT and brachytherapy with 14 patients also receiving 
concomitant ADT. Interestingly, one patient experienced a 
rise in PSA after TRT, which steadily declined thereafter, 
and only one patient with 5-year post-brachytherapy has 
a PSA greater than 0.5 ng/dL. In no patients documented 
recurrence, or progression of disease and for this reason, no 
men stopped TRT. Morales treated five hypogonadal men 
with TRT once the PSA nadir was reached after EBRT, and 
none had evidence of recurrence based on PSA or digital 
rectal exam (DRE) (27). Davila and co-workers reviewed 
six men treated with EBRT for Pca and treated with TRT. 
None of whom developed biochemical recurrence although 
the follow-up was of only 9 months after radiation course (28). 
While we have yet to see the randomized trial that will 
answer the question of risk associated with TRT in men Pca 
and treated by RT, there are interesting data that suggest 
as men with very low or low risk Pca according to National 
Comprehensive Cancer Network (NCCN) guidelines may 
be considered eligible for a treatment with TRT when 
clinically indicate. For patients with intermediate or high 
risk for recurrence who reach castration range during 
treatment with short- and long-term ADT, particular 
caution must be used. In fact, according with the saturation 
model, Pca is sensitive to T levels only in the castrate range, 
above which androgen receptors (ARs) are saturated and 
more T does not produce more growth (29). The picture is 
more clear in patients treated with RP, as any PSA elevation 
thereafter is concerning for disease recurrence. Some 
authors suggest that TRT may be optimal for men with “no 
residual disease,” which may be defined for patient treated 
with RP as a PSA <0.2 and <2 ng/mL for the post-radiation 
population (30). 
Morgentaler and co-workers studied a cohort of men 
with untreated Pca and treated with RTR for hypogonadal 
condition (31). Thirteen with these clinical characteristics 
received TRT for a median of 2.5 yrs. Gleason score at 
biopsy ranged from 6 to 7 in the 13 studied subjects. During 
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TRT mean serum testosterone concentration increased 
from 238 to 664 ng/dL and mean PSA as well as prostate 
volume did not significantly change. On re-biopsy, in 54% 
of subjects no evidence of Pca was observed, while two 
subjects experienced an upgrading of pathologic stage with 
no change in the oncological parameters during follow-up. 
No local progression or distant disease was observed in this 
study. Morales studied seven hypogonadal patients with 
untreated and treated Pca (32). Clinical criteria to stop TRT 
were (I) an increase in PSA level >1 ng/mL quarterly or (II) a 
PSA doubling time less than 12 months. After discontinuing 
TRT, a return to pretreatment PSA levels was an indication 
to reinitiate TRT. Four patients demonstrated unpredictable 
increases in PSA level, occurring immediately or as late as 
after 36 months after starting TRT. One patient with a rising 
PSA later underwent RP. In one patient, intermittent TRT 
resulted in synchronous changes in PSA levels.
Clinical experience with testosterone in men 
with castration resistant Pca
A body of biological and clinical evidence suggests that 
pulsed T treatment may have a positive impact on the 
biology of Pca. In this regard, an anti-proliferative effect 
from immediate T boosts within the physiological range was 
observed in androgen-sensitive Pca cells by other authors 
(33-35). Brendler at the Brady Urological Institute (36) 
used parenteral testosterone in a number of men with 
CRPC. He found a clinically significant improvement in 
several measurable parameters which included decreased 
pain, decreased prostate size and decreases in acid and 
alkaline phosphatase. Similarly, Prout and Brewer (37) 
administered parenteral testosterone in men who were 
either hormonal naive or recently or long-term castrates. In 
the long-term castrate group four of five men treated with 
testosterone for at least one month experienced clinical 
benefit. Of note, one man in this group with severe back 
pain, weakness and anorexia had a 10-month response with 
complete cessation of pain and decrease in acid phosphatase. 
On the contrary the five remaining patients received 
testosterone for less than 19 days and experienced tumor 
progression. More recently, Mathew (38) reported a case 
report on the use of testosterone gel replacement therapy 
in a man with castration-resistant prostate cancer (CRPC) 
and observed a sustained decrease in PSA that lasted 
for approximately one yr. Recently, two Phase I studies 
reported the results of the use of testosterone gel in men 
with CRPC. In the first study, Szmulewitz selected 15 men 
with rising PSA and minimal bone disease. He evaluated the 
effect of increasing doses of transdermal testosterone in this 
cohort of men with early CRPC (39). Groups of five men 
were treated with 2.5, 5.0, or 7.5 mg/day of transdermal 
testosterone reaching a serum concentrations T of 305, 
308, and 297 ng/dL, respectively. In this study only one 
patient had symptomatic progression whereas three patients 
had a decrease in PSA and men treated at the highest 
dose had a prolonged time to progression. No significant 
toxicity was observed in the studied cohort except one 
man who experienced grade 4 cardiac toxicity 53 weeks 
after T therapy. In the second study, Morris evaluated the 
effect of transdermal testosterone at a dose of 7.5 mg/day 
administered for 1 week, 1 month or until disease 
progression in small cohort of 12 patients with CRPC (40). 
They observed no grade 3 or 4 toxicities and no pain flares. 
Average serum testosterone levels were within normal 
limits and no objective responses were observed. Four 
patients had declines of PSA of at least 20% and 1 patient 
out of 12 achieved a >50% decline in PSA. These clinical 
results from a limited case series or case reports seem to 
suggest that systemic testosterone can be administered to 
men with CRPC and minimal disease burden. However 
no evidence exists that more advanced CRPC disease may 
respond to testosterone treatment as hormone sensitive Pca 
in early stage. Additionally no practical indications may be 
derived from this limited number of clinical evidence. A 
very comprehensive explanation of molecular events leading 
to tumour cell growth inhibition under rapid cycling of 
physiologic or supra-physiologic T boost may be explained 
by studies defining bipolar androgen therapy (BAT) 
(33-35). AR may function as a licensing factor for DNA 
replication, which may be important for the proliferation 
properties of Pca tumour cells (34). In this regard, without 
a timely and complete AR degradation during mitosis, the 
origin of DNA replication remains AR-bound stalling, 
in this way, the re-licensing for the subsequent cell cycle. 
Therefore, it seems clear that T level is a critical event in 
determining AR degradation. Rapid concentration changes 
obtained under both physiological and supra-physiological 
T supplementation may prevent AR degradation during 
mitosis, thus stabilising this receptor and resulting in G1/
S-phase growth arrest (34,41). 
Testosterone as protective biological determinant 
against the development or recurrent Pca
Although a low number of studies have investigated 
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men receiving TRT after RP, there is a lower rate of Pca 
recurrence and progression in this cohort of patients 
compared to subjects not receiving TRT after RP. Although 
most patients with Pca treated with surgical and non-
surgical treatment with curative intent may be considered 
oncologically cured, around 15% to 40% will experience a 
biochemical-recurrence (42). Interestingly the recurrence 
rates of subjects being treated with TRT after RP seems to 
be even lower than found in men a low risk of recurrence 
and not treated with TRT (21). The explanation of this 
paradox was explained by Sonnenschein who evaluated 
the biological response of LNCaP tumor cells to different 
concentrations of androgens (43). The evidence derived 
from this study seems to suggest that the proliferative 
response in this cellular model may be not directly 
mediated by intracellular ARs and those androgens were 
able to trigger an inhibition of cell proliferation at higher 
concentrations. Other authors suggested that testosterone 
may have a beneficial effect on Pca by promoting the 
insurgence of a less aggressive phenotype (44). 
New frontiers of Psychotherapy in men with 
hypogonadism and Pca
Most of the men live the experience of diagnosis and treatment 
of Pca with high levels of stress in all aspects of life.
Specifically, the diagnosis may prefigure itself not only 
as a threat to survival, but also to prospects for future well-
being of the patient in several ways: from the physical to the 
social, from the familiar to the sexual.
In fact, although many men often deal with great courage 
this experience, some have high levels of psychological and 
sexological stress (45,46).
On an equal age, men with Pca have a higher probability 
of having erectile dysfunction (ED) of 10-15 times (47). 
Other distressing effects associated with the treatment 
include shortening of the penis (68%), loss of sexual 
desire (60-80%), orgasms unsatisfactory (64-87%), sexual 
dissatisfaction overall (61-91%) (48,49). These effects may 
lead to altered sexual performance; changes in relationships 
with partners; progressive reduction in sexual fantasies and 
in self-esteem (49,50).
In addition, many men are hesitant to seek help from a 
sexual health expert (49). This is particularly problematic 
for men who have undergone RP, where a rapid return 
to sexual activity (3 months after the surgery), associated 
with couple therapy, may increase the recovery rate of 
spontaneous erections and improve responses to treatment 
for ED (51).
However, existing medical and support services are 
geared exclusively towards the patient, not paying enough 
attention to the couple’s relationship and ignoring the needs 
of the partner, who are less likely to consider their sexual 
needs and more focused on the physical and psychological 
recovery of their man (52,53).
The psychological distress of female partners may 
increase if they have a limited knowledge about the post-
operative course and treatment modalities.
In addition, female partners may be reluctant to share 
their discomfort with their partners, avoiding to adding 
new stress to the couple; This is even more likely when 
the discomfort regards the sexuality (52). This lack of 
communication leads the partner to live on their own 
and with limited tools anguish and anxiety derived from 
the male oncological pathology (54). The discomfort 
experienced by women is also aggravated by the demands 
of emotional support from their partners, which leads to 
having to manage not only their own anxiety, but also the 
anguish of their husbands (52,55). 
Patients and partner capacity to deal with Pca and 
subsequent treatment side effects are correlated (56) and 
may have a negative impact on the marital relationship (57). 
The reactions of the partner to sexual dysfunction and 
the support they provide seem to influence the level of 
acceptance of sexual changes experienced by humans (58). 
In addition, the ability of the female partner's pleasure 
during sexual activity (in the absence of overt dysfunction) 
is a strong predictor of improved sexual satisfaction in the 
male partner (49).
This leads to the need to provide targeted support to 
couples that promotes communication and adaptation to 
sexuality post-cancer. This strategy, for example, has led to 
excellent results in couples with women suffering from breast 
or gynaecological cancer and will promote communication 
strategies that included the topic of cancer (59).
In contrast to women, men are less likely to seek 
psychological help and are reluctant to use sexual aids 
effective after treatment of Pca, despite the high levels of 
sexual dissatisfaction with the results of treatment. The lack 
of engagement with psychosocial support programs after 
Pca has been described in connection to a conflict with the 
values that underpin masculine identities (60).
Effective support interventions need to use delivery 
methods and sources that are acceptable for this group of 
patients. Men prefer individual consultations to support 
sexuality after Pca (61). Specifically, the interventions most 
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accepted are Internet-based (62,63) and self-help groups, 
where discussions among peers provide emotional support 
and information, reducing the feeling of social isolation (64). 
A feasibility study of a program of support among patients 
with Pca reported a decrease of depressive symptoms and a 
better self-efficacy in the short term, with people who speak 
more frequently about incontinence, ED and prostate-
specific antigen test (65). In addition, a randomized 
controlled trial of a training program group focused on 
treatments for Pca (66), found that only with the addition 
of Peer discussion to the provision of information by an 
expert allow a better understanding and internalization of 
information, compared to a control group. An advantage 
of peer supportprovided by the patients veterans is that 
it is inexpensive compared to approaches provided by 
professional nurses.
Although this approach is very promising, currently 
there are no randomized controlled trials to evaluate the 
effectiveness of peer support in the reduction of psychological 
distress and sexual. However, the reduction of the costs of 
peer support than professional approaches, although not 
yet quantified, makes this a potentially lucrative source 
of support. As well, research to date has not identified an 
effective way to improve sexual and psychosocial adjustment 
for both men with Pca and their partners.
One of the latest interventions to improve sexual and 
psychosocial adjustment for both men with Pca and their 
partners is “Proscan for Couples” (67), a randomised 
control trial of a couples-based intervention that targets 
the specific challenges couples experience at diagnosis of 
localised Pca and after RP. Intervention components include 
psycho-education; cognitive behavioural strategies; couple 
relationship education focused on relationship enhancement 
and helping the couple to conjointly manage the stresses of 
cancer diagnosis and treatment; and specific psychosexual 
education and sexual communication. The protocol consisted 
of sexuality intervention DVD plus eight sessions of 
telephone support by peer support volunteers or professional 
nurse, planned from post-surgery to six months later.
This study has identified when distress in couple is 
highest during diagnosis period, and consequently realizing 
more specific and individual interventions trough a cost-
effective and easily translatable approach.
The impact of Pca and hypogonadism on the 
psychological well-being
It is well-known how Pca bears on psychological well-being. 
In fact, both the diagnosis and the relative treatment may 
lead to dramatic consequences, damaging the sexual and, in 
some cases, the general self-esteem. However, the negative 
relation between Pca and psychological well-being may be 
also reinforced by the hypogonadal condition, which, in 
some cases, may coexist with the cancer. 
Some studies have highlighted the impact of testosterone 
decrease on mood. In particular, a review (68) has evidenced 
the role of low testosterone levels in the development 
of anxiety and depression. In fact, it is known that 
hypogonadal men may suffer with more probability of 
anxiety disorders and major depressive disorder, compared 
to men with physiological androgens levels. Vice versa, 
several researches suggest that testosterone-replacement 
therapy in hypogonadal men may improve mood, alleviates 
anxiety, and mitigates symptoms of depression. This data 
remains, however, not replicable in all studies.
The suggestion of a worsening by the side of a 
low testosterone levels is given by another study (69) 
investigating the prevalence of sexual dysfunctions, anxiety, 
depression, and a poorer quality of life in young patients 
with congenital hypogonadotropic hypogonadism (CHH). 
As supposed by researchers, low endogenous levels of 
testosterone might be related to the increased incidence of 
psychological symptoms.
Hence, since the man with both a diagnosis of a Pca 
and of a hypogonadism may be of a major risk to develop 
anxiety disorders or major depressive disorder, this patient 
should be supported by a psychoterapic intervention, in 
order to re-establish the global well-being.
Conclusions
Clinical and biological data suggest no clear relationship 
between testosterone levels and growth of Pca above the 
range of castration. While no randomized controlled trials 
have been specifically conducted to answer to this clinical 
issue retrospective clinical data indicate that TRT may be 
used safely in highly selected men with Pca. The negative 
attitudes with respect to testosterone supplementation in 
men with hypogonadism and Pca may be justified by the 
relatively low number of clinical and preclinical studies 
that specifically dealt with how androgens affect Pca 
biology. More controversial still is the use of TRT in men 
in active surveillance or at intermediate or high risk of 
recurrence and treated by curative radiotherapy. In these 
clinical scenarios, clinicians should be aware that safety 
data regarding TRT are scanty limiting our ability to 
145Translational Andrology and Urology, Vol 4, No 2 April 2015
© Translational Andrology and Urology. All rights reserved. Transl Androl Urol 2015;4(2):139-147www.amepc.org/tau
draw definitive conclusions on this important topic. Long-
term data and more prospective or randomized studies 
are needed to conclusively change the current paradigm 
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